Today: 19 May 2026
Carvana stock slides after the bell as Wall Street ends 2025 lower — what investors watch next for CVNA
1 January 2026
2 mins read

Carvana stock slides after the bell as Wall Street ends 2025 lower — what investors watch next for CVNA

NEW YORK, December 31, 2025, 19:28 ET — After-hours

  • Carvana shares were down about 1.7% at $422.02 in after-hours trading.
  • The stock traded between $421.95 and $430.30 in the session, with about 1.6 million shares changing hands.
  • U.S. stocks slipped in the final session of 2025 in holiday-thin trade, with markets closed Thursday for New Year’s Day.

Carvana Co. shares slipped in after-hours trading on Wednesday, ending the final session of 2025 lower as investors wrapped up the year with light liquidity and a broad pullback in U.S. equities.

The move matters now because Carvana has become a high-volatility consumer name, and year-end trading tends to magnify swings as funds rebalance and tax-driven positioning fades. Thin volumes can exaggerate price moves in stocks that have been heavily traded through the year.

With U.S. markets shut on Thursday for New Year’s Day, investors are looking to Friday’s reopen for signs of whether risk appetite returns quickly in early January, or whether year-end profit-taking carries over into 2026.

Wall Street’s major indexes ended lower in the final trading session of 2025, with the S&P 500 down 0.74% and the Nasdaq down 0.76%, while volume stayed below recent averages in the holiday-shortened week, a Reuters market wrap showed. “I do not expect that the last few days will have so much bearing on the performance of the next year,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking opportunities when liquidity was low. Reuters

Carvana’s stock — often treated as a high-beta proxy for consumer credit and growth sentiment — moved in step with that late-year de-risking. After-hours trading refers to transactions after the 4 p.m. ET closing bell, when liquidity is typically thinner than during the regular session.

Used-vehicle and auto-retail names were broadly lower on the day. CarMax fell 1.7%, while ACV Auctions lost 1.5% and OPENLANE slid 1.1%, according to MarketWatch data.

Carvana has been in focus since it was selected to join the S&P 500 in December, a milestone that came after a sharp turnaround from its 2022 downturn as the online used-car retailer tightened costs and benefited from improved demand, Reuters reported.

Investors are also watching the rate outlook. The Federal Reserve meets on Jan. 27-28, with investors expecting the central bank to leave its benchmark rate unchanged, according to a Reuters report on Tuesday.

For Carvana, the calendar turns quickly to earnings season. Nasdaq lists Carvana’s next earnings report date as an estimate of Feb. 18, 2026, noting the timing is derived from an algorithm and is not a company-confirmed date.

Traders will be listening for any update on demand and profitability trends that drive the equity story, including retail unit volumes and gross profit per retail unit — the amount earned per car sold before overhead — as well as any commentary on funding conditions in a still-rate-sensitive consumer environment.

Near term, the stock’s direction may hinge less on company headlines than on whether Friday’s reopening brings fresh risk-taking after a choppy, low-liquidity finish to the year.

Stock Market Today

  • Fuller, Smith & Turner PLC Completes Share Buyback Driving Treasury Shares Higher
    May 19, 2026, 3:15 PM EDT. Fuller, Smith & Turner PLC (FSTA) bought 7,504 of its own "A" Ordinary Shares at an average price of 630 pence per share on May 19, 2026, through Deutsche Bank's trading arm, Deutsche Numis, continuing its share buyback programme launched in January 2026. The total listed issued shares now stand at 36.45 million, with 5.31 million shares held in Treasury. Treasury shares are those that the company repurchases and holds rather than canceling, often to support share prices or for future use. This latest transaction adjusts the total voting rights to 31.14 million shares, as per FCA rules on Disclosure and Transparency. Fuller's plans to retain the repurchased shares in Treasury as part of its ongoing capital management strategy.

Latest articles

Marvell Stock Is Jumping Again — The AI Chip Trade Has One Week To Prove It

Marvell Stock Is Jumping Again — The AI Chip Trade Has One Week To Prove It

19 May 2026
Marvell shares climbed 6.6% to $180.04 Tuesday, outperforming a falling Nasdaq as investors positioned ahead of its May 27 earnings call. Trading volume reached 15.3 million shares, with the company’s market value near $155.5 billion. The stock’s rally followed analyst price target hikes and speculation over AI data-center demand. Marvell last reported record annual revenue and forecast further growth led by its data-center business.
Enbridge Stock Hits a 52-Week High Even as Line 5 Fight Throws Up a Fresh Risk

Enbridge Stock Hits a 52-Week High Even as Line 5 Fight Throws Up a Fresh Risk

19 May 2026
Enbridge Inc. shares hit a 52-week high of C$78.25 on Tuesday, rising 2.76% even as the S&P/TSX Composite slipped 0.1% amid inflation concerns. The move came after the company reaffirmed 2026 financial guidance and despite a partial construction pause on its Line 5 project in Wisconsin. Pembina Pipeline shares also rose, though less sharply.
Amazon shares fall as $200 billion AI question lingers

Amazon shares fall as $200 billion AI question lingers

19 May 2026
Amazon shares fell 2.3% to $258.73 Tuesday, underperforming the S&P 500 and Nasdaq as investors trimmed tech holdings ahead of Nvidia’s earnings. AWS revenue jumped 28% to $37.6 billion last quarter, but Amazon’s free cash flow dropped to $1.2 billion over the past year from $25.9 billion, reflecting heavy AI spending.
Meta stock slips after-hours as scam-ad scrutiny mounts, Manus AI deal draws focus
Previous Story

Meta stock slips after-hours as scam-ad scrutiny mounts, Manus AI deal draws focus

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop